China Emerging As Big Winner In Pharma Outsourcing Rush To Asia - PwC
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Asia's expanding wealth and markets for drugs, combined with a pool of scientific talent and strengthening protections for patents, are propelling pharmaceutical multinationals to step up operations in the region in drug manufacturing, research and clinical trials
You may also be interested in...
Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech In $1.6 Billion Transaction
Deal hinges on approval by Beijing's antitrust czars.
Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech In $1.6 Billion Transaction
Deal hinges on approval by Beijing's antitrust czars.
Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech If $1.6 Billion Transaction Is Approved By Beijing's Antitrust Czars
BEIJING - With the globe's top pharmaceutical players outsourcing ever-expanding chunks of early-stage research to China, the Massachusetts-based Charles River Laboratories has launched a move to merge with China's leading contract research organization, WuXi PharmaTech, in a $1.6 billion transaction